Scientists at Harvard Medical School have identified a potential new way to generate insulin-producing cells from a patient’s own pancreatic cells. By disabling a gene called ALDH3B2, the researchers were able to reprogram pancreatic duct cells into beta-like cells capable of producing and releasing insulin. The discovery could eventually lead to new approaches for diabetes treatment by helping patients regenerate their own insulin-producing cells rather than relying entirely on insulin injections or transplanted beta cells. However, the research is still in its experimental stages and requires further investigation before it can be considered a treatment for people with diabetes.
Targeting the Loss of Insulin-Producing Beta Cells
Pancreatic beta (β) cells produce insulin, the hormone responsible for regulating blood glucose levels. In type 1 diabetes, the immune system destroys these cells. In type 2 diabetes, beta-cell dysfunction and progressive loss of beta-cell capacity contribute to the disease. Consequently, restoring functional beta cells has become an important goal in diabetes research. Researchers have explored several approaches, including transplanting insulin-producing cells from organ donors and creating beta cells from stem cells. However, these strategies face significant challenges, including limited donor availability, complex transplantation procedures and the need for immunosuppressive drugs to prevent rejection. The Harvard team therefore investigated a different possibility: Could a patient’s own pancreatic cells be reprogrammed to produce insulin?
Using CRISPR to Find the Genetic Brake
Instead of trying to make existing beta cells multiply—a process that occurs very slowly in humans—the researchers looked for biological mechanisms that could directly change the identity of other pancreatic cells. They focused on pancreatic duct cells, which are abundant in the pancreas but normally do not produce insulin. Using advanced CRISPR gene-editing technology, the researchers systematically screened more than 19,000 genes. Their objective was to identify genes that prevent duct cells from changing into insulin-producing beta-like cells. To track the transformation, the scientists genetically engineered human pancreatic duct cells with a molecular reporter that produced a signal when the cells acquired beta-cell characteristics.
The screen revealed a key candidate: ALDH3B2
ALDH3B2 Acts as a Molecular Brake. The researchers found that ALDH3B2 helps maintain pancreatic duct cells in their original identity. In other words, the gene acts like a molecular brake that prevents the cells from adopting a beta-cell-like state. When scientists silenced or removed ALDH3B2, that brake was released. The pancreatic duct cells subsequently switched off genes associated with duct-cell identity and activated genes associated with beta cells. These included genes involved in insulin production and processing. Under normal conditions, fewer than 1% of the human duct cells tested underwent this type of transformation. However, eliminating ALDH3B2 increased the conversion rate to approximately 8.5% in the researchers’ experiments.
Reprogrammed Cells Produce Insulin
The transformation involved more than simply switching on the insulin gene. The researchers observed changes in the cells’ genetic and epigenetic programming. After ALDH3B2 was silenced, the insulin gene lost chemical modifications called DNA methylation. This change left the gene more accessible, allowing the newly reprogrammed cells to maintain an insulin-producing state. Interestingly, the researchers found that the cells did not transform directly from pancreatic duct cells into mature beta cells. Instead, they temporarily moved through a more immature pancreatic progenitor-like state before developing characteristics of insulin-producing cells. This finding provides important clues about how pancreatic cells can change their identity and could help researchers develop more efficient methods for cell regeneration.
Reprogrammed Human Cells Improved Blood Glucose in Mice
The researchers next tested whether the reprogrammed cells could function inside a living organism. They transplanted the human cells into diabetic mice and observed that the cells survived and responded to changes in blood glucose levels by releasing human insulin. As a result, the mice’s blood glucose levels fell close to normal and remained controlled throughout the six-week study period. Although these results are encouraging, the experiment was conducted in mice and does not demonstrate that the approach is safe or effective in humans.
Could a Drug Replace Gene Editing?
One of the most interesting aspects of the discovery is that ALDH3B2 is an enzyme. That means researchers may not necessarily need to permanently edit the gene to achieve the same effect. Instead, a drug could potentially inhibit the enzyme’s activity and encourage pancreatic duct cells to change their identity. The researchers tested DEAB, a broad aldehyde dehydrogenase inhibitor, and observed a similar increase in the conversion of human pancreatic duct cells into beta-like cells. The results suggest that blocking ALDH3B2 activity may be sufficient to initiate the reprogramming process. However, DEAB affects multiple enzymes, so researchers will need to identify compounds that specifically target ALDH3B2 before considering a targeted drug-based approach.
A Potential New Direction for Diabetes Treatment
The potential impact of this research is significant. Diabetes affects hundreds of millions of people worldwide, and the global number of people living with the disease has increased dramatically over recent decades. Current treatments, including insulin therapy, glucose monitoring and other diabetes medications, can help manage blood glucose. Nevertheless, they do not fully reproduce the dynamic function of a healthy population of pancreatic beta cells. Cell replacement therapies offer another option, but donor shortages and immune rejection remain major obstacles. Generating insulin-producing cells from a patient’s own pancreas could potentially address some of these limitations. Because the cells originate within the patient’s body, researchers hope that future approaches could reduce or avoid some of the challenges associated with transplanted donor cells.
From Genetic Discovery to Future Therapy
The identification of ALDH3B2 as a regulator of pancreatic duct-cell identity provides a new avenue for diabetes research. The next challenge is to determine exactly how ALDH3B2 controls this cellular transformation and whether researchers can safely reproduce the process in the human pancreas. If future studies identify highly specific ALDH3B2-targeting compounds, the discovery could eventually contribute to therapies designed to stimulate the body’s own pancreatic cells to produce new insulin-producing beta-like cells. As reported by medicalxpress.com, for now, however, the findings represent an early-stage research breakthrough rather than an available diabetes treatment. Further laboratory studies, animal research and eventually carefully controlled human clinical trials will be necessary to determine whether this promising approach can be translated into a safe and effective therapy.